Adverse event—any—160/94 Duration of nine months 3 · COPD
Budesonide/formoterol (BDF) may leads to higher adverse event—any—160/94 Duration of nine months 3 compared with placebo (low certainty).
1 finding from 1 review
OR 1.32 [1.08, 1.61]
1556 participants
Low
All‐cause mortality ‐ formoterol and budesonide vs salmeterol and fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause mortality ‐ formoterol/budesonide vs salmeterol/fluticasone compared with salmeterol/ICS (low certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ formoterol/budesonide vs salmeterol/budesonide · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/budesonide… compared with salmeterol/ICS (low certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in asthma‐related non‐fatal serious adverse events ‐… compared with salmeterol/ICS (low certainty).
2 findings from 1 review
All‐cause mortality formoterol/budesonide vs salmeterol/budesonide · adults, chronic asthma: all‐cause mortality
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ formoterol and budesonide vs salmeterol and fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/budesonide… compared with salmeterol/ICS (moderate certainty).
1 finding from 1 review
Intervention not reported
Budesonide (2 RCTs; 106 participants) · surgically induced remission in Crohn's disease
It is very uncertain whether the intervention changes budesonide (2 RCTs; 106 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Budesonide (1 RCT; 43 participants) · surgically induced remission in Crohn's disease
The intervention showed no clear difference in budesonide (1 RCT; 43 participants) (low certainty).
1 finding from 1 review
ICS dose at final visit · children with asthma
1 finding from 1 review
Intervention not reported
Adverse events－serious events Budesonide/formoterol (BDF) versus budesonide (BD) · patients with COPD
It is very uncertain whether the intervention changes adverse events－serious events Budesonide/formoterol (BDF) versus… (very low certainty).
1 finding from 1 review
Number of participants experiencing one or more episode requiring treatment with oral steroids · adults and children with chronic asthma
Combination fluticasone/salmeterol showed no clear difference in participants experiencing exacerbations requiring oral steroid… compared with budesonide/formoterol (moderate certainty).
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · adults and children with chronic asthma
Combination fluticasone/salmeterol showed no clear difference in participants experiencing exacerbations requiring admission to… compared with budesonide/formoterol (moderate certainty).
1 finding from 1 review
Asthma‐related serious adverse event · adults and children with chronic asthma
Combination fluticasone/salmeterol showed no clear difference in asthma‐related serious adverse event compared with budesonide/formoterol (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults and children with chronic asthma
1 finding from 1 review
Withdrawals due to adverse events · adults and children with chronic asthma
Combination fluticasone/salmeterol showed no clear difference in withdrawals (adverse events) compared with budesonide/formoterol (moderate certainty).
1 finding from 1 review
Clinical improvement (dichotomous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Histological improvement (dichotomous) · active EoE pediatric patients
1 finding from 1 review
Histological improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (dichotomous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found